Navigation Links
GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
Date:7/9/2009

ARLINGTON, Va., July 9 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger on The Biotechnology Industry Organization's (BIO's) erroneous claims regarding the Senate HELP Biogenerics amendments.

"BIO's erroneous claims that anything less than an unprecedented 13 years of market exclusivity will harm innovation flies in the face of the recent Federal Trade Commission (FTC) report that such long periods of exclusivity are NOT needed to spark innovation. In fact, FTC suggested that because of their extremely robust intellectual property protection in this sector, 'no' to little market exclusivity is required.

"Both the White House and the Office of Management and Budget (OMB) also specifically stated that an unprecedented 12 to 14 years of market exclusivity would NOT achieve what should be our shared goal of balancing pharmaceutical innovation and much needed consumer access.

"While the generic industry still supports the proven successful Hatch-Waxman model as contained in the bipartisan 'Promoting Innovation and Access to Lifesaving Medicines Act,' we have commended the President for working to move this issue forward by recommending a

7-year exclusivity compromise.

"Countless Americans are waiting for more affordable biogenerics to treat their serious medical conditions and it is clear that 12 to 14 years of exclusivity will do nothing to get them the help they desperately need.

"It is a shame that in an attempt to protect the profits of Amgen, Genentech and other biotech companies, BIO and its supporters are misleading Congress. It's time to put patients over profits."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information about the industry, visit www.gphaonline.org.


'/>"/>
SOURCE Generic Pharmaceutical Association (GPhA)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
2. Retired Supreme Court Justice Sandra Day OConnor and Former House Speaker Newt Gingrich Address Senate Special Committee on Aging, Calling for Urgent Action Against Alzheimers Disease
3. National ePrescribing Patient Safety Initiative Supports Senates Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety
4. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
5. TechNet Urges Swift U.S. Senate Approval of FCC Nominees Julius Genachowski and Robert McDowell
6. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
7. Biogenerics Will Save Billions, Says Hospira CEO
8. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
9. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
10. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
11. Hospira Supports Newly Introduced Biogenerics Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):